A PHASE 3, DOUBLE-BLIND, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究旨在评估氨曲南赖氨酸盐雾化吸入(AI，Cayston)28天的安全性和有效性，以及在28天的妥布霉素雾化溶液(TSI，TOBI)治疗后，AI维持或改善临床状况的能力。这项研究的主要目的是评估吸入性或静脉注射抗菌素所需的时间。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to assess the safety and efficacy of a 28-day treatment with Aztreonam Lysinate for Inhalation (AI, Cayston) and the ability of AI to maintain or improve clinical status following a 28-day course of Tobramycin Solution for Inhalation (TSI, TOBI) therapy in cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA). The primary endpoint of this study is to evaluate the time to need for inhaled or IV antibotics.